Ubrogepant for the Acute Treatment of Migraine When Administered During the Prodrome (Premonitory Phase): Results From a Phase 3, Randomized, Double-blind, Placebo-Controlled, Crossover Study (S47.001)

David W Dodick,Joel M Trugman,Michelle Finnegan,Sung Yun Yu,Chengcheng Liu,Todd J Schwedt,Kaifeng Lu,Peter J Goadsby,Richard B Lipton,Lawrence Severt

doi:10.1212/wnl.0000000000202043

Ubrogepant for the Acute Treatment of Migraine When Administered During the Prodrome (Premonitory Phase): Results From a Phase 3, Randomized, Double-blind, Placebo-Controlled, Crossover Study (S47.001)

David W Dodick, Joel M Trugman + Show 8 more

https://doi.org/10.1212/wnl.0000000000202043

Copy DOI

Export

Save

Cite

Journal: Neurology	Publication Date: Apr 25, 2023
Citations: 6

Affiliation: Winneshiek Medical Center, AbbVie (United States), University of California, Los Angeles, Albert Einstein College of Medicine

#Received Research Support #Employee Of AbbVie #Consultant For Abbvie #Patient Centered Outcomes Research Institute #Intensity Headache #Scientific Advisory #Premonitory Phase #Ownership Interest #American Academy Of Neurology #Intellectual Interests

Abstract
Full-Text
Similar Papers

Abstract

Listen

Ubrogepant for the Acute Treatment of Migraine When Administered During the Prodrome (Premonitory Phase): Results From a Phase 3, Randomized, Double-blind, Placebo-Controlled, Crossover Study (S47.001)

Full Text

Published Version

Check institute access

Open DOI Link

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title

Journal

Date

Author

View more papers

More From: Neurology

Paper Title

Journal

Date

Author

View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.

R Discovery Prime

Ubrogepant for the Acute Treatment of Migraine When Administered During the Prodrome (Premonitory Phase): Results From a Phase 3, Randomized, Double-blind, Placebo-Controlled, Crossover Study (S47.001)